​

Seres Therapeutics (MCRB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MCRB Stock Forecast

Seres Therapeutics (MCRB) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $1.25, with a high of $1.25 and a low of $1.25. This represents a -84.55% decline from the last price of $8.09.

- $1 $2 $3 $4 $5 $6 $7 $8 $9 High: $1.25 Avg: $1.25 Low: $1.25 Last Closed Price: $8.09

MCRB Stock Rating

Seres Therapeutics stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (61.11%), 3 Hold (16.67%), 4 Sell (22.22%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 4 3 11 Strong Sell Sell Hold Buy Strong Buy

MCRB Price Target Upside V Benchmarks

TypeNameUpside
StockSeres Therapeutics-84.55%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$8.09$8.09$8.09
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-1---1
Mar, 26-12--3
Feb, 26-12--3
Jan, 26-12--3
Dec, 25-22--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 07, 2024Keay NakaeChardan Capital$1.25$0.8547.06%-84.55%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 12, 2024Cowen & Co.BuyBuyhold
Jun 07, 2024OppenheimerOutperformPerformdowngrade
May 09, 2024OppenheimerOutperformOutperformhold
Mar 06, 2024Chardan CapitalBuyBuyhold
Apr 28, 2023Chardan CapitalBuyBuyhold
Sep 07, 2022Piper SandlerOverweightOverweighthold
Jun 08, 2022JefferiesBuyupgrade

Financial Forecast

EPS Forecast

$-50 $-39 $-28 $-17 $-6 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-14.30$-46.29$-17.77$-18.86$0.64---
Avg Forecast$-0.62$-2.16$-0.99$-0.12$-0.33$-0.37$-0.29$-0.70
High Forecast$-0.62$-2.16$-0.91$-0.03$-0.15$0.05$0.05$-0.70
Low Forecast$-0.62$-2.16$-1.08$-0.30$-0.43$-0.76$-0.62$-0.70
Surprise %2206.45%2043.06%1694.95%15616.67%-293.94%---

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$144.93M---$789.00K---
Avg Forecast$149.82M$13.76M$126.07M$31.00M$33.08M$25.00M$125.00M$296.16M
High Forecast$149.82M$13.76M$126.43M$31.00M$33.08M$25.00M$125.00M$296.16M
Low Forecast$149.82M$13.76M$125.93M$31.00M$33.08M$25.00M$125.00M$296.16M
Surprise %-3.27%----97.62%---

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-65.58M$-250.16M$-113.72M$136.00K$5.70M---
Avg Forecast$-78.79M$-276.97M$-126.94M$-20.81M$-37.00M$-45.12M$-55.04M$-90.22M
High Forecast$-78.79M$-276.97M$-115.98M$-3.64M$-18.88M$6.94M$6.42M$-90.22M
Low Forecast$-78.79M$-276.97M$-137.89M$-37.98M$-55.12M$-97.19M$-79.61M$-90.22M
Surprise %-16.77%-9.68%-10.41%-100.65%-115.40%---

MCRB Forecast FAQ

Is Seres Therapeutics stock a buy?

Seres Therapeutics stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 3 Hold, 4 Sell, and 0 Strong Sell, reflecting a consensus that Seres Therapeutics is a favorable investment for most analysts.

What is Seres Therapeutics's price target?

Seres Therapeutics's price target, set by 18 Wall Street analysts, averages $1.25 over the next 12 months. The price target range spans from $1.25 at the low end to $1.25 at the high end, suggesting a potential -84.55% change from the previous closing price of $8.09.

How does Seres Therapeutics stock forecast compare to its benchmarks?

Seres Therapeutics's stock forecast shows a -84.55% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Seres Therapeutics over the past three months?

  • April 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 33.33% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 33.33% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.

What is Seres Therapeutics’s EPS forecast?

Seres Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.37, marking a -157.81% decrease from the reported $0.64 in 2025. Estimates for the following years are $-0.29 in 2027, and $-0.7 in 2028.

What is Seres Therapeutics’s revenue forecast?

Seres Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $25M, reflecting a 3068.57% increase from the reported $789K in 2025. The forecast for 2027 is $125M, and $296.16M for 2028.

What is Seres Therapeutics’s net income forecast?

Seres Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-45.124M, representing a -892.21% decrease from the reported $5.7M in 2025. Projections indicate $-55.039M in 2027, and $-90.217M in 2028.